Physician profile
David L Beaton
NPI 1376508572
$1,255.31
in general payments reported to CMS, 2019-2025
20 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $46.89 · 2021: $13.27 · 2022: $86.54 · 2023: $297 · 2024: $409 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $292.75 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $129.37 | 2023-2025 | Myfembree |
| Abbvie INC. | $128.65 | 2019 | |
| Smith+Nephew, INC. | $102.34 | 2023-2025 | Grafix Pl, Stravix, Stravix Mesh |
| Pfizer INC. | $98.09 | 2021-2024 | |
| Stryker Corporation | $86.67 | 2024 | Blueprint Patient Specific Instrumentation |
| Myovant Sciences INC. | $64.51 | 2022 | |
| Therapeuticsmd, INC. | $50.89 | 2019 | |
| Ucb, INC. | $45.11 | 2024 | Nayzilam |
| Daiichi Sankyo INC. | $42.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.86 | 2019-2023 | |
| Mallinckrodt Enterprises LLC | $30.63 | 2019 | |
| Organon LLC | $22.04 | 2023 | Nexplanon |
| Axonics, INC. | $22.03 | 2022 | |
| Hologic Sales and Service, LLC | $20.22 | 2024 | Aptima |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.88 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $16.12 | 2020 | |
| Grifols USA, LLC | $16.09 | 2020 | |
| Becton, Dickinson and Company | $15.04 | 2024 | Bd Onclarity |
| Glaxosmithkline, LLC. | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.